PO.CH01.04 · 化学

利用合成细菌孢子实现RNA的靶向递送

Targeted delivery of RNA using synthetic bacterial spores

海报缩略图:利用合成细菌孢子实现RNA的靶向递送
编号 6380 展板 12 时间 4/21 02:00–05:00 区域 Section 38 主讲 Federico Machinandiarena, Dr PH
分会场 Drug Delivery
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Federico Machinandiarena, Domenico D'Atri, David J. Fitzgerald, Kumaran S. Ramamurthi

NIH-NCI, Bethesda, MD

摘要 Abstract

中文摘要
背景:RNA疗法在治疗多种疾病方面展现出日益广阔的前景。然而,递送RNA通常需要将其包封于脂质纳米颗粒中,而该技术的一个局限在于难以实现除肝脏和肾脏以外的组织特异性。我们此前报道了一种类合成细菌孢子样颗粒,称为"SSHELs",用于靶向货物递送[1]。SSHELs由确定的、生物相容性材料构成,已被证明可特异性结合HER2阳性癌细胞并在肿瘤中蓄积[2]。本研究探讨SSHELs能否将RNA递送至组织特异性部位,重点关注HER2阳性细胞。 方法:实验方法包括蛋白纯化、SSHEL组装、mRNA和siRNA载入,以及通过共聚焦显微镜和流式细胞术评估RNA递送特异性。开展了体外和体内实验以评估靶细胞中EGFP和荧光素酶的产生。实验模型包括细胞培养和小鼠。 结果:通过用抗HER2 affibody修饰SSHELs并调节脂质组成,我们实现了向HER2阳性细胞的特异性mRNA和siRNA递送,从而实现选择性的蛋白诱导或沉默。SSHELs载入RNA的效率极高(约95%),每个颗粒可产生数千个转录本。在进一步研究中,我们观察到用DOTAP制备的SSHELs具有一个独特特征:它们不会引发或抑制炎性细胞因子的产生(如TNF-alpha、IL-6)。这一特性值得关注,因为它提示以DOTAP配制的SSHELs具有生物相容性和免疫惰性。正在进行的体内实验正在评估载有mRNA的SSHELs向HER2阳性肿瘤递送货物的疗效。 结论:SSHELs因其独特特性代表了RNA治疗学中的一种新方法。这些颗粒模拟细菌孢子结构,为小分子、多肽和RNA等众多治疗药物的靶向递送提供了一个生物相容且用途广泛的平台。 参考文献:Wu, I.-L., et al. (2015). A versatile nano display platform from bacterial spore coat proteins. Nature Communications, 6, 6777. Kong, M., D'Atri, D., et al. (2023). Cell-specific cargo delivery using synthetic bacterial spores. Cell Reports, 42(1), 111955.
查看英文原文 English abstract
Background: RNA therapy holds increasing promise for the treatment of various diseases. Delivering RNA, however, typically requires encapsulation in lipid nanoparticles, and a limitation of this technology is achieving tissue specificity beyond the liver and kidneys. We previously reported synthetic bacterial spore-like particles, termed “SSHELs,” for targeted cargo delivery [1]. SSHELs, composed of defined, biocompatible materials, were shown to specifically bind to HER2-positive cancer cells and accumulate in tumors [2]. This study explores whether SSHELs can deliver RNA to tissue-specific locations, focusing on HER2-positive cells. Methods: The experimental approach involved protein purification, SSHEL assembly, mRNA and siRNA loading, and assessing RNA delivery specificity via confocal microscopy and flow cytometry. In vitro and in vivo assays were conducted to assess the production of EGFP and luciferase in target cells. Experimental models included cell cultures and mice. Results: By decorating SSHELs with anti-HER2 affibodies and modulating lipid composition, we achieved specific mRNA and siRNA delivery to HER2-positive cells, resulting in selective protein induction or silencing. Loading SSHELs with RNA was highly efficient (~95%), yielding thousands of transcripts per particle. In further investigations, we observed a distinctive feature of SSHELs made with DOTAP: they did not elicit or suppress inflammatory cytokine production (e.g., TNF-alpha, IL-6). This characteristic is noteworthy, as it suggests the biocompatibility and immunologically inert nature of SSHELs formulated with DOTAP. Ongoing in vivo experiments are assessing the efficacy of mRNA-loaded SSHELs in delivering cargo to HER2-positive tumors. Conclusions: SSHELs represent a novel approach in RNA therapeutics due to their unique characteristics. These particles, which mimic the structure of bacterial spores, provide a biocompatible and versatile platform for the targeted delivery of myriad therapeutics, such as small molecules, peptides, and RNAs. References: Wu, I.-L., et al. (2015). A versatile nano display platform from bacterial spore coat proteins. Nature Communications , 6, 6777. Kong, M., D'Atri, D., et al. (2023). Cell-specific cargo delivery using synthetic bacterial spores. Cell Reports , 42(1), 111955.
利益披露 Disclosure
F. Machinandiarena, None.. D. D'Atri, None. D. J. Fitzgerald, Cyclo Therapeutics Stock. K. S. Ramamurthi, None.

← 返回 AACR 2026 检索